Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Ionut-Gabriel Funingana"'
Autor:
James Spicer, Bristi Basu, Ana Montes, Udai Banerji, Rebecca Kristeleit, Rowan Miller, Gareth J. Veal, Christopher J. Corrigan, Stephen J. Till, Mariangela Figini, Silvana Canevari, Claire Barton, Paul Jones, Sarah Mellor, Simon Carroll, Chris Selkirk, George Nintos, Vineet Kwatra, Ionut-Gabriel Funingana, Gary Doherty, Hannah J. Gould, Giulia Pellizzari, Mano Nakamura, Kristina M. Ilieva, Atousa Khiabany, Chara Stavraka, Jitesh Chauhan, Cheryl Gillett, Sarah Pinder, Heather J. Bax, Debra H. Josephs, Sophia N. Karagiannis
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-11 (2023)
Abstract All antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers the potential for enhanced effector cell potency. Here we report a Phase I dose escalation trial (NCT025
Externí odkaz:
https://doaj.org/article/10c6fe5134614037a52da348794ee12d
Autor:
Philip Smith, Thomas Bradley, Lena Morrill Gavarró, Teodora Goranova, Darren P. Ennis, Hasan B. Mirza, Dilrini De Silva, Anna M. Piskorz, Carolin M. Sauer, Sarwah Al-Khalidi, Ionut-Gabriel Funingana, Marika A. V. Reinius, Gaia Giannone, Liz-Anne Lewsley, Jamie Stobo, John McQueen, Gareth Bryson, Matthew Eldridge, The BriTROC Investigators, Geoff Macintyre, Florian Markowetz, James D. Brenton, Iain A. McNeish
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Abstract The drivers of recurrence and resistance in ovarian high grade serous carcinoma remain unclear. We investigate the acquisition of resistance by collecting tumour biopsies from a cohort of 276 women with relapsed ovarian high grade serous car
Externí odkaz:
https://doaj.org/article/1ccafbd33afa4d399a8e68fd7523c12c
Autor:
Tristan Barrett, Simon Pacey, Kelly Leonard, Jerome Wulff, Ionut-Gabriel Funingana, Vincent Gnanapragasam
Publikováno v:
European Urology Open Science, Vol 38, Iss , Pp 17-24 (2022)
Background: Active surveillance (AS) is a preferred management option for men with prostate cancer with favourable prognosis. However, nearly half of men on AS switch to treatment within 5 years, so therapeutic strategies to prevent or delay disease
Externí odkaz:
https://doaj.org/article/7a238cec1f2c4a68acfa08e379669d70
Autor:
Philip Smith, Thomas Bradley, Lena Morrill Gavarró, Teodora Goranova, Darren P. Ennis, Hasan B. Mirza, Dilrini De Silva, Anna M. Piskorz, Carolin M. Sauer, Sarwah Al-Khalidi, Ionut-Gabriel Funingana, Marika A. V. Reinius, Gaia Giannone, Liz-Anne Lewsley, Jamie Stobo, John McQueen, Gareth Bryson, Matthew Eldridge, The BriTROC Investigators, Geoff Macintyre, Florian Markowetz, James D. Brenton, Iain A. McNeish
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/7fa144d3f1d843cdbc178d67b28d1d98
Autor:
Leonardo Rundo, Lucian Beer, Lorena Escudero Sanchez, Mireia Crispin-Ortuzar, Marika Reinius, Cathal McCague, Hilal Sahin, Vlad Bura, Roxana Pintican, Marta Zerunian, Stephan Ursprung, Iris Allajbeu, Helen Addley, Paula Martin-Gonzalez, Thomas Buddenkotte, Naveena Singh, Anju Sahdev, Ionut-Gabriel Funingana, Mercedes Jimenez-Linan, Florian Markowetz, James D. Brenton, Evis Sala, Ramona Woitek
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundPathological response to neoadjuvant treatment for patients with high-grade serous ovarian carcinoma (HGSOC) is assessed using the chemotherapy response score (CRS) for omental tumor deposits. The main limitation of CRS is that it requires
Externí odkaz:
https://doaj.org/article/e4977050f91b4e03bdf1f1d2431f3e79
Autor:
Ionut-Gabriel Funingana, Pubudu Piyatissa, Marika Reinius, Cathal McCague, Bristi Basu, Evis Sala
Publikováno v:
Cancers, Vol 14, Iss 20, p 5076 (2022)
Clinical trials for oncology drug development have long relied on surrogate outcome biomarkers that assess changes in tumor burden to accelerate drug registration (i.e., Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria)
Externí odkaz:
https://doaj.org/article/279342882e514e5094bfd43e5b10db00
Autor:
Susana Banerjee, Vasiliki Michalarea, Joo Ern Ang, Alvaro Ingles Garces, Andrea Biondo, Ionut-Gabriel Funingana, Martin Little, Ruth Ruddle, Florence Raynaud, Ruth Riisnaes, Bora Gurel, Sue Chua, Nina Tunariu, Joanna C. Porter, Toby Prout, Mona Parmar, Anna Zachariou, Alison Turner, Ben Jenkins, Stuart McIntosh, Ed Ainscow, Anna Minchom, Juanita Lopez, Johann de Bono, Robert Jones, Emma Hall, Natalie Cook, Bristi Basu, Udai Banerji
Publikováno v:
Clinical Cancer Research. 28:4634-4641
Purpose: CT900 is a novel small molecule thymidylate synthase inhibitor that binds to α-folate receptor (α-FR) and thus is selectively taken up by α-FR–overexpressing tumors. Patients and Methods: A 3+3 dose escalation design was used. During do
Autor:
Udai Banerji, Bristi Basu, Natalie Cook, Emma Hall, Robert Jones, Johann de Bono, Juanita Lopez, Anna Minchom, Ed Ainscow, Stuart McIntosh, Ben Jenkins, Alison Turner, Anna Zachariou, Mona Parmar, Toby Prout, Joanna C. Porter, Nina Tunariu, Sue Chua, Bora Gurel, Ruth Riisnaes, Florence Raynaud, Ruth Ruddle, Martin Little, Ionut-Gabriel Funingana, Andrea Biondo, Alvaro Ingles Garces, Joo Ern Ang, Vasiliki Michalarea, Susana Banerjee
Supplementary Figure from A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2704c4994794b5ac32f8afd095444629
https://doi.org/10.1158/1078-0432.22489008
https://doi.org/10.1158/1078-0432.22489008
Autor:
Udai Banerji, Bristi Basu, Natalie Cook, Emma Hall, Robert Jones, Johann de Bono, Juanita Lopez, Anna Minchom, Ed Ainscow, Stuart McIntosh, Ben Jenkins, Alison Turner, Anna Zachariou, Mona Parmar, Toby Prout, Joanna C. Porter, Nina Tunariu, Sue Chua, Bora Gurel, Ruth Riisnaes, Florence Raynaud, Ruth Ruddle, Martin Little, Ionut-Gabriel Funingana, Andrea Biondo, Alvaro Ingles Garces, Joo Ern Ang, Vasiliki Michalarea, Susana Banerjee
Supplementary Table from A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0475121ba5d79aa5db6a42030c640f34
https://doi.org/10.1158/1078-0432.22488999
https://doi.org/10.1158/1078-0432.22488999
Autor:
Udai Banerji, Bristi Basu, Natalie Cook, Emma Hall, Robert Jones, Johann de Bono, Juanita Lopez, Anna Minchom, Ed Ainscow, Stuart McIntosh, Ben Jenkins, Alison Turner, Anna Zachariou, Mona Parmar, Toby Prout, Joanna C. Porter, Nina Tunariu, Sue Chua, Bora Gurel, Ruth Riisnaes, Florence Raynaud, Ruth Ruddle, Martin Little, Ionut-Gabriel Funingana, Andrea Biondo, Alvaro Ingles Garces, Joo Ern Ang, Vasiliki Michalarea, Susana Banerjee
Purpose:CT900 is a novel small molecule thymidylate synthase inhibitor that binds to α-folate receptor (α-FR) and thus is selectively taken up by α-FR–overexpressing tumors.Patients and Methods:A 3+3 dose escalation design was used. During dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2962569a9f2efd37fe6e40c644a7cac
https://doi.org/10.1158/1078-0432.c.6532860
https://doi.org/10.1158/1078-0432.c.6532860